A Single-center Study Designed to Evaluate the Safety and Efficacy of Tulipon

NCT04268758 | Withdrawn

• 1 other identifier: Tulipon-HMO-CTIL
• Study Type: observational
• Target: N/A
• Locations: 0 countries
• Sites: N/A

Brief Summary

Subjects who normally use tampons will use Tulipon device during one menstrual cycle. Baseline and post usage clinical evaluation will be performed for safety testing.

Conditions

Safety Issues

Outcome Measures

Primary Outcomes (1)

• safety and efficacy of the Tulipon.

  We will take vaginal cultures to show no vaginal infection. By questionnaire we will find out about leakage of period blood from the Tulipon.

  1 month

Interventions

tulipon DEVICE

Tulipon is a new kind of hygienic device, used to collect the secreted menses during the bleeding phase of the menstruation.

Eligibility Criteria

• Age: 18 Years - 45 Years
• Gender Eligibility Details: women only.
• Age Groups: Adult (18-64)
• Sampling Method: Non-Probability Sample

Study Population

Adult females with normal monthly menstruation.

You may qualify if:

• Women aged 18-45 years
• Regular menstrual cycles (21-35 days)
• Uses tampons every month for the last 2 months to handle their monthly bleeding.
• Active Bleeding lasts at least 3 days
• Willing not to change their feminine care or hygiene practices during their participation in the study (except as directed by the protocol and instructions for participants)
• Non-pregnant, with no intentions to get pregnant during the clinical trial
• Willing to use pads provided thought the study only for the duration of this study
• Subject is able to comply with all the requirements of the study and agrees to participate in all the activities of the study
• Signed written informed consent form (ICF) to participate in the study

You may not qualify if:

• Pregnant or lactating women
• Gave birth less than a 12 month prior to the study.
• Virgin
• Using medications to manage pain during active bleeding
• Using intrauterine device or intrauterine device with hormones (Mirena)
• Had experienced Toxic shock syndrome (TSS)
• Previous diagnosis of primary or secondary dysmenorrhea
• Previous diagnosis of endometriosis
• Experiences urinary incontinence
• Suffers from uterus or urine prolapse
• Abnormal findings following the gynecological exam
• Subjects with a known or suspected sensitivity to any of the device materials (Polyethylene, Polyurethane, Nylon, Cotton)
• Been through a vaginal operation in the last 6 months prior to the study.
• Participation in current or recent clinical trial within 30 days prior to baseline visit

Sponsors & Collaborators

• Hadassah Medical Organization: lead
• Gals Bio Ltd.: collaborator

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 10, 2020
• First Posted: February 13, 2020
• Study Start: June 1, 2021
• Primary Completion: December 1, 2021
• Study Completion: December 1, 2021
• Last Updated: August 4, 2022

Record last verified: 2020-04